This cross-sectional study investigates whether there are regional disparities in prior authorization requirements for combined tenofovir disoproxil fumarate and emtricitabine with qualified health plans and assesses if any qualified health… Click to show full abstract
This cross-sectional study investigates whether there are regional disparities in prior authorization requirements for combined tenofovir disoproxil fumarate and emtricitabine with qualified health plans and assesses if any qualified health plan characteristics explain the disparities.
               
Click one of the above tabs to view related content.